Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRTX NASDAQ:LRMR NASDAQ:NCNA NASDAQ:ONCT NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTXGalera Therapeutics$0.03-6.3%$0.03$0.02▼$0.14$2.01M1.8994,829 shs270,617 shsLRMRLarimar Therapeutics$3.48+0.6%$2.54$1.61▼$11.20$221.54M0.86841,952 shs708,572 shsNCNANuCana$0.06-1.0%$0.11$0.03▼$10.79N/A1.4247.79 million shs587.06 million shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.77$1.56M1.1891,303 shsN/AORMPOramed Pharmaceuticals$2.12-2.3%$2.20$1.82▼$3.09$88.64M1.59141,600 shs26,946 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTXGalera Therapeutics+3.27%+9.23%+19.33%+9.65%-79.71%LRMRLarimar Therapeutics+4.22%+11.25%+30.08%+94.38%-60.93%NCNANuCana+8.45%+6.73%-20.87%-91.68%-97.96%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-92.71%ORMPOramed Pharmaceuticals+3.83%+0.46%-2.69%+1.88%-13.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRTXGalera Therapeutics0.3005 of 5 stars0.03.00.00.00.61.70.0LRMRLarimar Therapeutics1.5166 of 5 stars3.61.00.00.01.11.70.0NCNANuCana2.5297 of 5 stars3.32.00.00.01.12.51.3ONCTOncternal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals0.2858 of 5 stars0.03.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRTXGalera Therapeutics 0.00N/AN/AN/ALRMRLarimar Therapeutics 3.11Buy$18.50431.61% UpsideNCNANuCana 2.50Moderate Buy$25.0041,776.05% UpsideONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ORMP, NCNA, ONCT, LRMR, and GRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/24/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.006/24/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ANCNANuCanaN/AN/AN/AN/A$1.34 per shareN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05ORMPOramed Pharmaceuticals$1.34M64.63N/AN/A$3.61 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRTXGalera Therapeutics-$59.08M-$0.26N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.490.00N/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)NCNANuCana-$24.28M-$7.020.00N/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/AORMPOramed Pharmaceuticals-$19.06M-$0.440.00N/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)Latest ORMP, NCNA, ONCT, LRMR, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025LRMRLarimar Therapeutics-$0.4877N/AN/AN/AN/AN/A6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/A5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRTXGalera TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRTXGalera TherapeuticsN/A9.749.74LRMRLarimar TherapeuticsN/A7.487.48NCNANuCanaN/A1.251.25ONCTOncternal TherapeuticsN/A2.392.39ORMPOramed PharmaceuticalsN/A23.9423.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRTXGalera Therapeutics50.77%LRMRLarimar Therapeutics91.92%NCNANuCana44.00%ONCTOncternal Therapeutics16.05%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipGRTXGalera Therapeutics12.90%LRMRLarimar Therapeutics4.50%NCNANuCana31.20%ONCTOncternal Therapeutics11.20%ORMPOramed Pharmaceuticals13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableNCNANuCana306.08 million4.18 millionNot OptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionableORMP, NCNA, ONCT, LRMR, and GRTX HeadlinesRecent News About These CompaniesORMP - Oramed Pharmaceuticals Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMOramed Pharmaceuticals Inc. (ORMP) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comORMP - Oramed Pharmaceuticals Inc Executives - MorningstarJune 27, 2025 | morningstar.comMWe're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn RateJune 27, 2025 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above Fifty Day Moving Average - Should You Sell?June 24, 2025 | marketbeat.comOramed Pharm Extends Stock Buyback ProgramMay 21, 2025 | tipranks.comThe past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableMay 17, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | finanznachrichten.deOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | prnewswire.comAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed PharmaceuticalsApril 28, 2025 | globenewswire.comORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 TrialApril 3, 2025 | finance.yahoo.comOramed Pharmaceuticals And 2 Other Penny Stocks With Promising PotentialMarch 15, 2025 | finance.yahoo.comOramed Pharmaceuticals Issues Letter to ShareholdersMarch 4, 2025 | prnewswire.comOraMed Enters Global Licensing Deal for Lidocaine ProductMarch 1, 2025 | investing.comCongressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals StockFebruary 27, 2025 | benzinga.comOramed Pharmaceuticals to Spin Off Its Protein Oral Delivery TechnologyFebruary 11, 2025 | contractpharma.comCOraTech to pioneer oral insulin with $75 million investmentFebruary 11, 2025 | msn.comOramed enters JV for insulin development and commercializationFebruary 11, 2025 | markets.businessinsider.comOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral InsulinFebruary 11, 2025 | prnewswire.comScilex announces early installment payment on senior secured promissory noteDecember 16, 2024 | markets.businessinsider.comORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent AgreementsDecember 2, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, NCNA, ONCT, LRMR, and GRTX Company DescriptionsGalera Therapeutics NASDAQ:GRTX$0.03 0.00 (-6.34%) As of 03:38 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Larimar Therapeutics NASDAQ:LRMR$3.48 +0.02 (+0.58%) Closing price 04:00 PM EasternExtended Trading$3.41 -0.07 (-1.90%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.NuCana NASDAQ:NCNA$0.06 0.00 (-1.00%) Closing price 04:00 PM EasternExtended Trading$0.06 0.00 (-2.01%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/29/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Oramed Pharmaceuticals NASDAQ:ORMP$2.12 -0.05 (-2.30%) Closing price 04:00 PM EasternExtended Trading$2.13 +0.01 (+0.71%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.